

DETECTION OF B1 GENE IN TOXOPLASMOSIS USING PCR AMONG PREGNANT WOMEN ATTENDING ANTENATAL CLINIC IN KADUNA STATE NORTHWEST NIGERIA.

ABSTRACT

BACKGROUND: Acute infection of *Toxoplasma gondii* can be transmitted during pregnancy to the foetus vertically which may cause congenital complications like abortion, stillbirth, visual impairment, seizure, hearing impairment and other neurological disorders.

METHODOLOGY: A total of 357 pregnant women were screened using ELISA method for acute *Toxoplasma gondii* (IgM) and detect the B1 gene of the organism using Polymerase Chain Reaction (PCR) across the three Senatorial zones of Kaduna state.

RESULT: The investigation however shows a prevalence of 2.8% (IgM). Ages 16-20 and 26-30 years have the highest prevalence of 3(0.8%) positive each. While ages 21-25 and 31-35 years have prevalence of 2(0.6%) positive each. However ages 36-40 years are all negative. The Mean age of 3.76, Standard Deviation = 1.157; $p > 0.05$. This did not show any statistical significant with the age groups. The PCR analysis confirmed the Toxoplasmosis by detecting the B1 gene in the peripheral blood of 9 out of 10 positive samples.

CONCLUSION: Therefore the chance of acquiring acute infection with *T. gondii* is high during pregnancy and the infection would have potential tragic outcomes for the mother, and new-born despite the fact that it can be prevented. This suggest the need for aggressive awareness and necessary facilities available for screening of *T. gondii* during antenatal clinic.

KEY WORDS: Toxoplasmosis, IgM, PCR, B1 gene.

INTRODUCTION

Toxoplasmosis is a zoonosis, caused by the obligate intracellular protozoan (1,2). This disease poses major public health challenge in congenital infections causing seizure, mental retardation, hearing impairment and visual loss, it is however transmitted to humans by ingestion of oocysts, or through accidental ingestion of sporulated oocysts from the environment (3,4). Alternatively, it can result from consumption of water or food contaminated by oocysts excreted in the faeces of infected cats (5,6).

The disease is an important food-borne pathogen and may also be transmitted by blood and blood products, organ transplants or by the ingestion of tachyzoites in unpasteurized milk (7,8). In fact, toxoplasmosis was once a leading infectious cause of food-borne death after Salmonellosis and listeriosis in the USA (9). Among several domestic animals cat is the definite host and play significant role in the spread of toxoplasmosis because they are the only animals that excrete resistant oocysts into the environment. However pigs, cattle, sheep, goats and rodents may play role in its transmission. Rats and mice are thought to be persistent wildlife host

reservoirs of *T. gondii* (10,11). One of the major challenges of the parasite in human is once they are infected with the parasite, they continually harbour the organism throughout life since human defence mechanisms cannot eliminate the cyst of *Toxoplasma* (12).

Globally approximately 10% of congenital *Toxoplasma* infections result in abortion or neonatal death. In 10-23% of congenital infections, signs are present at birth; these may include hydrocephalus, chorioretinitis, hepatosplenomegaly, and microcephaly. Clinical signs of congenital *Toxoplasma* infection are not apparent at first in 67-80% of cases (13). A significant proportion of encephalitic patients can also present with neuropsychiatric disorders including psychosis, dementia, anxiety, and personality disorder (14). Ocular toxoplasmosis may occur in up to one third of children that survive congenital infection and is the most common cause of intraocular inflammation in the world (15). Hearing loss has also been reported in 10%-30% and developmental delay in 20%-75% of this group of patients (16). Seroprevalence varies considerably high up to 50% with countries where raw meat is commonly eaten and in tropical regions of Latin America or Sub-Saharan Africa where cats are numerous and the climate is favourable for oocysts survival (17).

The chance of acquiring acute infection with *T. gondii* is high during pregnancy and the infection would have potential tragic outcomes for the mother, the foetus and new-born despite the fact that it can be prevented (18). In spite of the wide practice of keeping cats as domestic animals and presence of stray cats around, and suitable climatic conditions favoring survival of the parasite in the study area, to our knowledge, there is no regular serological screening of pregnant women for *T. gondii* infection (19). Research has been shown that over 90% of women who contract *T. gondii* infection remain asymptomatic and spontaneously recover, only a small proportion will develop clinical signs of the disease (20,21).

The clinical presentation in pregnant women is not more severe than in non-pregnant women and most often occurs as an influenza-like illness with an incubation period of 5-18 days following exposure (22). Seroprevalence varies greatly in geographical regions within a country and within different ethnic groups according to different environments, social customs, and habits of different populations (23,24,25,26).

Epidemiological studies suggest that prevalence of *T. gondii* infection in pregnant women varies greatly among different countries with prevalence estimates from US studies having a range of 3%–42%, Britain 22%, Netherland 80%, Korea 3.7%, Sudan 34.1%, Senegal 40.2%, New Zealand 33%, Iran 38.1%, Ethiopia 93.3% Dutch 26% and 41.6-66.9% in other Asian countries such as India and Jordan (27,28,29,30,31,17,32,33,34,35). In Southern Turkey anti-*Toxoplasma* IgG and IgM antibody was found to be 52.1% and 0.54% respectively. Therefore, infections due to *T. gondii* are considered a worldwide zoonosis of great public health importance (36, 37).

Worldwide prevalence rate of latent *Toxoplasma* infections in HIV-infected patients varies greatly from 3% to 97% (38,19). In sub-Saharan Africa, toxoplasmosis often remains undetected and untreated due to insufficient diagnostic procedures (39). Several studies have shown a consistently high *T. gondii*-seroprevalence for this region, ranging from 35% to 84% in different African countries south of Sahara (28).

In Nigeria the seroprevalence rates of toxoplasmosis by serological investigations have been estimated from 7% to 51.3% in normal pregnant women to 17.5% to 52.3% in women with abnormal pregnancies and abortions, while in Lagos 16.7% prevalence was reported for IgM antibodies in First trimester and 46.7% for IgG at third trimester. A study conducted in Zaria also reported prevalence of 29.1% for chronic and 0.8% for acute infections respectively. (40,41,38,42).

However, despite the recognized public health importance of *T. gondii* in different parts of the world, studies on the prevalence of toxoplasmosis among people and congenital disease danger posed on neonate and children there is no measures taken for prevention on pregnant women and even children who are venerable to the disease in Nigeria.

MATERIALS AND METHOD

STUDY AREA

The study was a cross sectional study carried out in some selected Hospital in Kaduna State, spread across the three Senatorial political Zones. Kaduna State is a old Capital of Northern Nigeria, is located in the north-western geopolitical zone of Nigeria and lies between Longitude 605 and 838 east of Greenwich meridian and latitude, 903 and 1132 north of equator. It has an estimated population of six million people with a total land mass estimated at 46,020sqKm in 23 local Government Areas. It shares borders with Zamfara, Katsina, Kano, Bauchi, Plateau, Nasarawa Niger States and Abuja (43).

STUDY POPULATION

The study population was pregnant women attending antenatal clinics in some selected State General Hospitals in the three Senetorial district of Kaduna State.

Inclusion Criteria

Pregnant women of all ages at all trimesters

Those attending antenatal clinic in Government Hospitals selected in Kaduna State

Those that gave consent for the investigation

Exclusion Criteria

Non pregnant women

Those not attending antenatal in Government Hospitals selected within Kaduna State

Those that decline consent for the investigation

Study Population

Multistage sampling was used in the selection of the study hospitals one each in the three Senatorial district of Kaduna state using random sampling method. In view of the above Gambo Sawaba General Hospital in the northern Senatorial District, Yusuf Dan Tsoho General Hospital in the Central Senatorial District and Kafanchan General Hospital in the Southern Senatorial District were selected.

SAMPLE SIZE

The sample size was calculated using the descriptive studies formula (Ishaku, *et al.*,2009)

$$n = \frac{z^2 pq}{d^2}$$

Where the P = Value of proportion of interest (If no information is known about p then p= 0.5).

A prevalence of 29.1% was used for the calculation (38).

d= Tolerance eg: within 0.05

$$\text{Hence: } n = \frac{1.96^2 \times 29.1/100 (1-29.1)}{0.05^2} = 317 \text{ samples.}$$

Therefore a total of 349 samples was collected across the three geopolitical zones of Kaduna State due to 10% additional anticipated non response rate and to minimize sampling error.

MATERIALS

The materials used are Vacutainers, serum microtubes, cotton wool, methylated spirit, specific Toxo- IgM EIA Kits, micropipettes of different sizes, distilled water, absorbent paper, micro-titer plate, strip well washer and micro- plate reader with 450nm wavelength and structured questionnaire.

ETHICAL CONSIDERATION

The ethical permission was obtained from the Kaduna State Ministry of Health Review Ethical Committee in a letter with reference number: MOH/ADM/744/VOL. 1/527 before sample was collected from the hospitals.

SAMPLE COLLECTION

Five millilitres of blood was collected by a qualified Medical laboratory Scientist/Technician via the ante cubical vein by applying tourniquet on either of the arm for visibility of the vein then swapping the area with cotton wool soaked in alcohol after which using sterile vacutainer/syringe and a needle is pierce into the vein for blood collection and then transfer the blood into a sterile plain tube and EDTA tubes 2.5ml each and labelled appropriately. The blood in the plain container was centrifuged at 3000rpm for 5minutes and the sera was harvested into clean cryovials and stored at -20°C while the 2.5ml in the EDTA was also stored at same temperature until it is required for use.

QUESTIONNAIRE ADMINISTRATION

The patient's information were collected using a designed structured questionnaire. Age, literacy level, source of drinking water, type of meat consumed, pets contact, obstetric history and milk consumed. The study was however explained to the patients and informed consent obtained before administering the questionnaire. In order to ensure confidentiality, names of patients were not recorded. The questionnaire was interpreted in local language for those who could not understand English.

SAMPLE ANALYSIS

Serological Method

Commercial sample reagent for specific detection of anti-*Toxoplasma gondii* IgM antibodies were used according to manufacturers manual purchased from CALBIOTECH Inc., USA. The reagent contain serum diluent to remove Rheumatoid factor and human IgG interference, the wells are coated with purified antigen. IgM specific antibodies, if present binds to the antigen. All unbound materials are washed away and the enzyme conjugate is added to bind to the antibody-antigen complex, if present. Excess enzyme conjugate is washed off and substrate is added. The plate is incubated to allow the hydrolysis of the substrate by the enzyme. The intensity of the colour generated is proportional to the amount of IgM specific antibody in the sample.

MOLECULAR DIAGNOSIS

IgM positive samples were selected and transported using ice pack to maintain cold chain of -20°C to University of Maiduguri, Biotechnology Centre Molecular Laboratory. The DNA was extracted from the samples using Phenol Extraction Method. Samples were amplified using Gel Electrophoresis Machine to detect a fragment from the *T. gondii* B1 gene, which is present in 35 copies and is conserved in the *T. gondii* genome, as described by Burg. *et al.*, (1989)

DNA was quantified using NanoDrop 2000C spectrophotometer (Thermos Scientific, USA). Concentration was determined based on absorbance at 260nm. Purity was estimated as ratio of absorbance at 260nm to Absorbance at 280nm (A260:A280).

Nested PCR amplification of *T. gondii* B1, (PCR for beta Haemoglobin)

PCR was run for human Hb-beta subunit to ascertain the quality of the extracted DNA, the viability of the tissue for PCR detection of Toxoplasma DNA and as a control gene for human tissues. A primer which targets a 122 bp sequence of the Hb beta sub-unit was used; primer was obtained commercially from Inqaba Biotec West Africa with the sequence as shown in the table. PCR reaction was carried out in 50µL reaction using FIREPol® master mix (Solis BioDyne, Estonia), each reaction containing 2.5 mM MgCl₂, 200 µM dNTPs in equimolar concentration in standard buffer. The following Thermocycler (Eppendorf mastercycler nexus, Hamburg, Germany) program was used; Initial Denaturation at 94°C for 5min followed by 35 cycles of denaturation at 95°C, 30 Sec; annealing at 56°C for 30sec and extension at 72°C for 30 sec.

First PCR for B1 gene

The first PCR to detect toxoplasma DNA was carried out using a primer set as shown in the table that targets a 197 bp section of the B1 gene. PCR reaction was carried out as explained above using the following thermocycler conditions; Initial Denaturation at 94°C for 5min followed by

35 cycles of denaturation at 95⁰C, 30 Sec; annealing at 46⁰C for 30 Sec and extension at 72⁰C for 30 Sec.

Second Nested PCR

The nested PCR amplifies a 97 bp region within the B1 gene. The PCR product obtained from the first PCR was used as template and primers used are as stated on the table. PCR conditions were carried out using the reaction conditions as explained above and thermocycler conditions are; Denaturation at 94⁰C for 5min followed by 35 cycles of denaturation at 95⁰C, 30 Sec; annealing at 53.5⁰C for 30 Sec and extension at 72⁰C for 30 Sec.

Gel Electrophoresis

To confirm amplification of the 122 bp *Hb beta* sub unit, 197 bp B1 gene and 97 bp nested PCR, agarose gel electrophoresis was carried out on 2.5% agarose in TAE buffer according to method suggested by Green and Sambrook (2012)(45). Electrophoresis was carried out at 90V for 60min and viewed under UV trans-illuminator. A 100 kb size ladder (*NEB*) was used as the standard size DNA marker for the beta hemoglobin and B1 gene while a 50kb ladder was used for the nested B1 gene. Staining was done with Ethidium Bromide.

RESULT

Table 1: Prevalence of *Toxoplasma gondii* (IgM) in pregnant women based on age group in Kaduna State.

Age Group(year)	No. Examined	IgM pos (%)	IgM neg (%)	P-Value
16-20	47	3(0.8)	44(12.3)	0.630 ^a
21-25	113	2(0.6)	111(31.1)	
26-30	106	3(0.8)	103(28.9)	
31-35	63	2(0.6)	61(17.1)	
36-40	22	0(0.0)	22(6.2)	
41-45	6	0(0.0)	6(1.7)	
TOTAL	357	10(2.8)	347(97.2)	

KEY: a = Pearson Chi-square test, Pos = Positive, Neg= Negative, % = Percentage




Figure 1. Gel image for amplification human hemoglobin beta (hbb).

This PCR amplifies a 122 bp section of the human Hb beta subunit to ascertain that samples are of human source and that the DNA is amplifiable.

UNDER PEER REVIEW




PLATE (I). Gel images of B1 gene for nested PCR showing amplification of a 197 bp fragment in samples 1, 2, 3, 4,5, 6, 8, 9 and 10.

KEY : LANE 1 = LADDER 100Kb

LANE 2 = POSITIVE SAMPLE

LANE S1-S10 = SAMPLES 1-10

LANE S1,S2,S3,S4,S5,S6,,S8, S9, and S10 shows B1gene at 197bp




PLATE (II). Gel image of second PCR which amplifies a 97 bp region within the 197 bp region of the B1 gene of *Toxoplasma gondii* amplified during the first PCR.

KEY : LANE 1 = LADDER 100Kb

LANE (POS +) = POSITIVE CONTROL

LANE (NEG -) = NEGATIVE CONTROL

LANE S1-S10 = SAMPLES 1-10

LANE S1,S2,S3,S4,S5,S6,S8, S9, and S10 shows B1gene at 97bp

NOTE: No amplification was observed in sample S7, and Negative Control (NEG-) while positive control shows distinct amplification

Table 2. Showing the Primer sequence and the Annealing Temperature

Primer sequence	Annealing Temp (°C)	Target region	Amplicon size	Reference
5'CTTCTGACACAACCTGTGTTCACTAGC3' 5'TCACCACAACCTCATCCACGTTCCACC 3'	56	Human Hemoglobin beta	122 bp	
5'GGAAGTGCATCCGTTTCATGAG3' 5'TCTTTAAAGCGTTCGTGGTC3'	46	B1 gene	197 bp	
5'TGCATAGGTTGCAGTCACTG3' 5' GCGACCAATGTGCGAATAGACC3'	53.5	B1 gene (nested)	97 bp	



UNDER PEER REVIEW

DISCUSSION

Acute infection of *Toxoplasma gondii* can be transmitted during pregnancy to the foetus vertically which may cause congenital complications like abortion, stillbirth, visual impairment, seizure, hearing impairment and other neurological disorders (46). This study observed 2.80% prevalence of Toxoplasmosis IgM antibodies similar to the work that reported 3.9% cases in India, 3.26% in Brazil, 2.6% in Gabon, 2.4% in New Zealand, and 0.8% in Zaria, (47,30,38,48,49,50,51). The findings in this study is however not similar to studies of 13.08% reported in Kano, 5.2% in Qatar, 11.5% in Portharcourt, 11.9% in Trinidad Tobago, 5.4% in Gabon, 7.6% in Lagos, and 7.2% in Maiduguri (52,42,53,54,55). The difference in the various prevalence rates could be due to geographical location, climate condition, and cultural behaviour even within same country because the parasite oocyst sporulation is prevalent in warm and humid condition (56).

The observed prevalence of IgM antibodies in the age group 16-20 and 26-30 years is in agreement with Kefale *et al.*, 2015 (19), who reported 20% prevalence in 15-19 years and Ballah *et al.*, 2017 (55) who reported < 20 years 52.86%. This may be attributed to several factors which could have been responsible for variation among the different age groups. Some of which may include the level of maturity, personal hygiene and socio-economic status of the family and even the level of their education because most of this women are under aged, and had teenage marriage which is common in Northern Nigeria.

Several studies have shown that PCR has been consistently used to detect DNA of *T. gondii* in various biological samples due to the fact that is more sensitivity in diagnosis compared to serological tests and culture (57). The first PCR method for *T. gondii* detection, targeting the B1 gene, was established in 1989(44). However since then this method has been widely used in prenatal diagnosis of congenital toxoplasmosis and *T. gondii* infection in immunocompromised patients (58,59,60,61,62).

Most PCR-based techniques make use of the B1 gene, and less commonly the SAG-1 (P-30) single-copy sequence, which has been shown to be a satisfactory PCR target for the detection of *T. gondii* (63). Unfortunately despite the several studies in Kaduna there is little or no molecular detection reported on toxoplasmosis investigations. In this study however out of 10 samples that

were positive serologically, only 9 that B1 gene *Toxoplasma gondii* DNA was detected and amplified at 97 bp region within the 197 bp region, therefore the presence of *Toxoplasma* DNA in the peripheral blood indicates a recent infection that is likely to be clinically significant and confirmed the sensitivity and specificity of PCR analysis for detecting recent infection in early pregnancy. This is in agreement with previous reports that PCR is recommended over serologic techniques for diagnosis of toxoplasmosis (57). However, the 1 out of 10 positive samples that B1 gene was not detected could be as result of false positive by the ELISA analysis which signifies that PCR is more sensitive and precise than ELISA test.

5.2. CONCLUSION

Toxoplasmosis is important in overall risk of its congenital infection from acute infection during pregnancy which has been shown in the absence of appropriate treatment. *Toxoplasma gondii* infected neonates have been shown to be at substantial risk of developing long-term sequelae when no treatment is given and the chance of acquiring acute infection with *T. gondii* is high during pregnancy which would have potential tragic outcomes for the mother, and new-born despite the fact that it can be prevented. This suggest the need for aggressive awareness and compulsory screening of *T. gondii* during antenatal.

REFERENCE

- (1). Calderaro A, Gorrini C, Montecchini S, Peruzzi S, Piccolo G, Rossi S, Gargiulo F, Manca N, Dettori G, Chezzi C (2010). Evaluation of a real-time polymerase chain reaction assay for the detection of *Dientamoeba fragilis*. *Diagnostic Microbiology and Infectious Disease*.; **67**(3):239-45.
- (2). Kamani, J., Mani, A.U., Kumshe, H.A., Dogo, G.I., Yidawi, J.P., Dauda, P., Nnabuife, H.E., Peter, J., and Egwu, G.O. (2010). Serosurvey for *Toxoplasma gondii* in dogs in Maiduguri, Borno State, Nigeria. *The Journal of Infection in Developing Countries* **4**(1): 015-018
- (3). Dubey, J.P. (2004). Toxoplasmosis –A Water Borne Zoonosis. *Veterinary Parasitology*, **126**: 57-72
- (4). Dawson, D. (2005). Food borne protozoan parasites. *International journal of Food Microbiology*, **103**:207-227
- (5). Vesco, G., Buffolano, W. La Chiusa. S. Mancuso, G. Caracappa, S. Chianca, A. Villari, S., Curro, V. Liga, F. and Petersen, E. (2007) *Toxoplasma gondii* infections in sheep in Sicily, Southern Italy. *Veterinary Parasitology*, **146**:3-8.
- (6). Lashari, M.H., and Tasawar, Z. (2010) Seroprevalance of Toxoplasmosis in Sheep in Southern Punjab, Pakistan. *Pakistan Veterinary Journal*. **30**(2):91-94.
- (7). Pereira KS, Franco RM, Leal DA, (2010) Transmission of Toxoplasmosis (*Toxoplasma gondii*) by foods. *Adv food Nutr Res*.; **60**:1-19.
- (8). Montoya, J. G. and Resso, F. (2005). Diagnosis and management of Toxoplasmosis clinics in perinatology. **32**:705-726
- (9). Jones, J.L., Lopez, A. Wilson, M., Schulkin, J. and Gubbs, R. (2001). Congenital toxoplasmosis: a review. *Obstetrics and Gynecology Survey*, **56**:296-305
- (10). Glazebrook, J. S., R. S. Campbell, G. W. Hutchinson and N. D. Stallman. (1978). Rodent zoonoses in North Queensland: the occurrence and distribution of zoonotic infections in North Queensland rodents. *Australia. Journal Experimental. Bioliology. Medical. Science*. **56**:147-56
- (11). Webster, J. P. (1994). Prevalence and transmission of *Toxoplasma gondii* in wild brown rats, *Rattus norvegicus*. *Journal. Parasitology*. **108**:407-11
- (12). Torgerson PR, Mastriacovo P. (2013) The global burden of congenital toxoplasmosis: A systematic review. *Bulletin of the World Health Organization*.; **91**(7):501-8.
- (13). Boyer KM, Holfels E, Roizen N, Swisher C, Mack D, Remington J, Withers S, Meier P, McLeod R, and the Toxoplasmosis Study Group (2005) Risk factors for *Toxoplasma gondii* infection in mothers of infants with congenital toxoplasmosis: implications for prenatal management and screening. *Am J Obst Gynecol* **192**:2557–2564

- (14). Torrey, E. F. and Yolken, R. H., (2003) “*Toxoplasma gondii* and Schizophrenia,” *Emerging-Infectious Diseases*, **9** (11) pp. 1375–1380,
- (15). Perry DD, Meritt JC. (1983) Congenital ocular toxoplasmosis. *J Natl Med Assoc.* **75**(2):169- 174.
- (16). Wong, S.Y. and Remington, J. (1994). Toxoplasmosis in pregnancy. *Clinical Infectious Diseases*, **18**:853-862
- (17). Borkakoty BJ, Borthakur AK, Gohain M. (2007) Prevalence of *Toxoplasma gondii* infection amongst pregnant women in Assam, India. *Indian J Med Microbiol*; **25**:431-432.
- (18). Rorman E, Zamir CS, Rilkis I, Ben-David H. (2006) Congenital toxoplasmosis prenatal aspects of *Toxoplasma gondii* infection. *Reprod Toxicol.*; **21**:458 – 72
- (19). Kefale Awoke, Endalkachew Nibret, Abaineh Munshea (2015) Sero-prevalence and associated risk factors of *Toxoplasma gondii* infection among pregnant women attending antenatal care at Felege Hiwot Referral Hospital, northwest Ethiopia *Asian Pacific Journal of Tropical Medicine* **8**(7):549–554
- (20). Kravetz, J.D. and Federman, D.G. (2005). Prevention of Toxoplasmosis In Pregnancy: Knowledge Of Risk Factors. *Infectious Diseases Of Obstetric Gynecology*, **13**(3):161-165.
- (21). Di Carlo, P.A. Romano, M.G. Schimmenti, A. Mazzola and Titone, L. (2008) Materno-fetal *Toxoplasma gondii* infection Critical review of available diagnostic methods. *Infez Med.* **16**: 28-32
- (22). Paquet, C., Yudin M.H. and Trois-Rivieres Q.C (2013). Toxoplasmosis in Pregnancy: Prevention, Screening and Treatment. *J. Obstet Gynaecol Can.*, **35**: 78-81
- (23). Contini, C. “Clinical and diagnostic management of toxoplasmosis in the immunocompromised patient,” *Parassitologia*, vol. **50**, no. 1-2, pp. 45–50, 2008.
- (24). Vital, J. E. Hernandez, A. V. Penalva de Oliveira, A. C. Dauar, R. F. Barbosa Jr., S. P. and Focaccia, R (2005) Cerebral toxoplasmosis in HIV-positive patients in Brazil: clinical features and predictors of treatment response in the HAART era,” *AIDS Patient Care and STDs*, vol. **19**, no. 10, pp. 626–634, 2005.
- (25). Conrad, P. A. Miller, M. A. Kreuder, C. ., (2005) Transmission of *Toxoplasma*: clues from the study of sea otters as sentinels of *Toxoplasma gondii* flow into the marine environment,” *International Journal for Parasitology*, vol. **35**, no. 11-12, pp. 1155–1168, 2005

- (26). Chan, B. T. E. Amal, R. N. Noor Hayati, M., (2008) Seroprevalence of toxoplasmosis among migrant workers from different Asian countries working in Malaysia,” *Southeast Asian Journal of Tropical Medicine and Public Health*, vol. **39**, no. 1, pp. 9–13,.
- (27). Fayo O, Leye A, Dieng Y, Richard-Lenoble D, Diallo S. (1998)Toxoplasmosis in Dakar. Seroepidemiologic sampling of 353 women of reproductive age. *Bull Soc Pathol Exot.* **91**:249–250.
- (28). Tenter, A.M, Heckerroth, A.R and Weiss, L.M. (2000).*Toxoplasma gondii*: From Animals to Humans. *International Journal of Parasitology*, **30**: 1217-1258.
- (29). Elnahas, A., Gerais, A. S., Elbashir, M. I., Eldien, E. S. and Adams, I (2003). Toxoplasmosis in Sudanese pregnant women. *Saudi Medical Journal*, **24**: 868-870.
- (30). Morris, A. and Croxson, M. (2004) Serological evidence of *Toxoplasma gondii* infection among pregnant women in Auckland. *New Zealand Medical Journal*, **117**: 770-776
- (31). Nash, J. Q., Chissel, S., Jones, J., Warburton, F. and Verlander, N. Q.(2005). Risk factors for toxoplasmosis in pregnant women in Kent, United Kingdom. *Epidemiology and Infections*, **133**: 475-483
- (32). Masini, L.L. Casarella, R.L. Grillo, M.P. Zannella and G.C. Oliva, (2008) Epidemiology study on anti *Toxoplasma gondii* antibodies prevalence in an Obstetric population. *Italian J. Gynaecol Obstet.* **20**: 159-166
- (33). Han, K.Shin, D.W. Lee T.Y. and Lee Y.H (2008) Seroprevalence of *Toxoplasmosis gondii* infection and risk factors associated with sero positivity of pregnant women in Korea. *J. Parasitol*, **94**:963-965
- (34). Henriquez S.A., Brett, R., Alexander, J., Pratt, J. and Roberts, C.W (2009). Neuropsychiatric disease and *Toxoplasma gondii* infection. *Neuroimmunomodulation.* **(2)**: 122-133.
- (35). Dagnachew, M. Yitayih W. Yeshambel B. Feleke M. Mengistu E. Getachew F. Gashaw Y. and Digsu N. (2013) Prevalence of *Toxoplasma gondii* and Associated Risk Factors among People Living with HIV at Gondar University Hospital, Northwest Ethiopia *ISRN Tropical Medicine Volume 6(2):23-26*
- (36). Nissapatorn, V., Noor, Azmi, M. A., Cho, S. M., Fong, M. Y., Init, I., Rohela, M., Khairual Anuar, A., Quek, K. F. and Latt, H. M. (2003). Toxoplasmosis: Prevalence and risk factors. *Journal of Obstetrics and Gynaecology*, **23**:618-624.
- (37). Ocaks, S, Zeteroglu S, Ozer C, Dolapcioglu K, Gungoren A. Seroprevalence of *Toxoplasma gondii*, rubella and cytomegalovirus among pregnant women in southern Turkey. *Scand. J. Infect. Dis.* **39(3)**: 231- 234

- (38). Ishaku.B., Ajoji, I.,Umoh, J. U.Laway, I. and Randawa, A. J. (2009).Seroprevalence of and risk factors for *Toxoplasma gondii* infection among antenatal women in Zaria, Nigeria. *Research Journal in medicine and medical science*, **4**:483-488.
- (39). Lindstrom, I., Kaddu-Mulindwa, D.H., Kironde, F. and Lindh, J. (2006). Prevalence of latent and reactivated *Toxoplasma gondii* parasites in HIV-patients from Uganda, *Acta Tropica* **100**:218–222.
- (40). Aganga,A.O., Umoh,J.U., Ekwrempu,C.C. and Kyewalabye, E.K. (1990). Prevalence studies of human toxoplasmosis infection in Zaria, Nigeria. *Nigerian Journal of Parasitology* **9**(11); 159 – 164
- (41). Olise, T., Gross, U. and Ajayi, J. (1996). High prevalence of toxoplasmosis during pregnancy in Nigeria. *Scandinavian journal of infectious diseases*, **28**:645-646
- (42). Deji-Agboola, A.M., Busari, O.S., Osinupebi, O.A. And Amoo, A.O.J.(2001). Seroprevalence Of *Toxoplasma gondii* Antibodies Among Pregnant Women attending antenatal clinic of Federal Medical Centre Lagos, Nigeria. *International Journal of biomedical Research*,**2**(41):1135-1139
- (43). Kaduna State Prevention and Strategic Behavioural Communication Strategy Document 2010-2015, Kaduna State AIDS Control Agency pp9 :www.kadsaca.org.
- (44). Burg J L, Grover C. M, Pouletty P, Boothroyd J C. (1989) Direct and sensitive detection of a pathogenic protozoan, *Toxoplasma gondii*, by polymerase chain reaction. *J Clin Microbiol.* **27**:1787 – 92.
- (45). Green, M.R. and Sambrook, J. (2012): Molecular Cloning: A Laboratory Manual press. 4th Edition. New York Cold spring Harbour. pp 26
- (46). Weiss LM, Kim K.(2004) The International Congress on Toxoplasmosis. *Int J Parasitol.* **2004**;34: 249-
- (47). Pelloux H, Burn E, Vernet G, Marcilat S, Jolivet M (1998). Determination of Anti-*Toxoplasma gondii* Immunoglobulin G Avidity: Adaptation to the Vidas System.*Diagn. Microbiol. Infect. Dis.* **32**: 69-73
- (48). Vaz, R.S., Thomaz-Soccol, V., Sumikawa, E., Guimarães, A.T.B. (2010). Serological prevalence of *Toxoplasma gondii* antibodies in pregnant women from Southern Brazil, *Parasitology Research***106**:661–665.
- (49). Abu-Madi MA, Al-Molawi N, Behnke JM.(2008) Seroprevalence and Epidemiological Correlates of *Toxoplasma gondii* infections among patients referred for hospital –based serological testing in Doha Qatar. *Parasit Vectors.* **2008**;1:39

- (50). Mickoto BM, Akue JP, Bisvigou U, Tsonga S M, Nkoghe D. Serological study on toxoplasmosis among pregnant women from Franceville, *Gabon Bull Soc Pathol Exot.* **103** (1):41-43
- (51). Malarvizhi A.1, Viswanathan T.2, Lavanya V.1, Arul Sheeba Malar S.1 and Moorthy K. (2012) Seroprevalence of *Toxoplasma gondii* in pregnant women *Journal of Public Health and Epidemiology Vol. 4(6), pp. 170-177,*
- (52). Ramsewaki, S., Randall, G., Koteswaramma, G., Nadira, S. and Abiodun, A.(2008) Seroprevalence and Risk factors of *Toxoplasma gondii* infection among pregnant women in Trinidad Tobago *Revista panamericana de salud publica* <https://www.scielosp.org>
- (53). Idris Abdullahi Nasir, Adekola Hafeez Aderinsayo, Hadiza Umar Mele and Maryam Muhammad Aliyu, (2015). Prevalence and Associated Risk Factors of *Toxoplasma gondii* Antibodies among Pregnant Women Attending Maiduguri Teaching Hospital, Nigeria. *Journal of Medical Sciences, 15: 147-154*
- (54). Umar, A. H. (2016). Seroprevalence and Risk Factors Associated with *Toxoplasma gondii* among pregnant women attending Antenatal Care in Kano Metropolitan Northwest Nigeria. Pp **2:** 6-25.
- (55). Ibinabo Laura Oboro, Orikomaba Korifama Obunge, Kennedy Tamunoimiegbam Wariso(2016) :Sero-epidemiology of Toxoplasmosis among Pregnant Women in the University of Port Harcourt Teaching Hospital, Nigeria *The Nigerian Health Journal, Volume 16* No 1,32-36
- (56). Ogo, F. M. (2016) Seroprevalence and factors Associated with Toxoplasmosis among pregnant women receiving Antenatal Care in Plateau State Nigeria. Pp**2:**21-39.
- (57). Gashout Aisha , Ahmad Amro, Mabruk Erhuma, Hamida Al-Dwibe, Eanas Elmaihub, Hamouda Babba, Nabil Nattah, and Abdalhafid Abudher(2016) Molecular diagnosis of *Toxoplasma gondii* infection in Libya *BMC Infect Dis. 16: 157.*
- (58). Parmley SF, Goebel FD, Remington JS. (1992).Detection of *Toxoplasma gondii* in cerebrospinal fluid from AIDS patients by polymerase chain reaction. *J.Clin Microbiol. 30:*3000–2.
- (59). Ho-Yen, D.O., Joss, A.W.L., Balfour, A.H., Smyth, E.T.M., Baird, D., Chatterton, J.M.W. (1992). The use of the polymerase chain reaction to detect *Toxoplasma gondii* in human blood samples. *Journal of Clinical Pathology. 45: 910-913.*83
- (60). Khalifa K-S, Roth A, Roth B, Arasteh KN, Janitschke K. (1994).Value of PCR for evaluating occurrence of parasitemia in immunocompromised patients with cerebral and extracerebral toxoplasmosis. *J Clin Microbiol. 32:*2813–9.

- (61). Hohlfeld P, Daffos F, Costa JM, Thulliez P, Forestier F, Vidaud M.(1994) Prenatal diagnosis of congenital toxoplasmosis with a polymerase-chain-reaction test on amniotic fluid. *New Engl J Med.* **331**:695–9
- (62) Lamoril J, Molina JM, de Gouvello A, Garin YJ, Deybach JC, Modai J,(1996). Detection by PCR of *Toxoplasma gondii* in blood in the diagnosis of cerebral toxoplasmosis in patients with AIDS. *J Clin Pathol.* **49**:89–92
- (63). Carlo Contini, Margherita Giuliadori, Rosario Cultrera and Silva Seraceni (2006) Detection of clinical-stage specific molecular *Toxoplasma gondii* gene patterns in patients with toxoplasmic lymphadenitis *Journal of Medical Microbiology*, **55**, 771–774

ACKNOWLEDGEMENT: This is to acknowledge WHO Measles laboratory at Yusuf Dansoho Hospital Tudun Wada Kaduna State. where the ELISA analysis was done under the supervision of MLS Peter Elisha.